Altimmune ALT
$2.08 +$0.11 (+5.58%)
Market closed · Nov 6, 8:10 pm ET · Last extended-hours $2.07 -0.48%
Open$1.97
Prev close$1.97
Day range$1.95 – $2.10
Volume2.77M
Market cap$404.60M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q2, ended Jun 2026
Revenue$0.00-100.0% YoY
Operating profit-$26.23M-14.4% YoY
Net profit-$22.83M-3.1% YoY
Diluted EPS-$0.12+55.6% YoY
Free cash flow-$24.25M-25.3% YoY
Operating cash flow-$24.22M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin-323,306.5%
Net margin-296,000.0%
Return on equity-28.9%
Return on assets-25.6%
Return on invested capital-29.2%
Current ratio26.78
Liabilities / assets10.1%
Cash & investments$326.28M
Total debt$35.75M
Net cash (debt)$290.54M
Income statement
| Line item | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $0.00 | $0.00 | $41,000.00 | $26,000.00 | $5,000.00 |
| Total Operating Revenue | $0.00 | $0.00 | $41,000.00 | $26,000.00 | $5,000.00 |
| Operating Expense | $26.23M | $24.24M | $94.53M | $28.92M | $20.86M |
| Selling and Admin Expenses | $7.57M | $8.05M | $28.10M | $10.51M | $5.90M |
| -General & Admin Expense | $7.57M | $8.05M | $28.10M | $10.51M | $5.90M |
| Research & Development | $18.66M | $16.19M | $66.43M | $18.41M | $14.96M |
| Operating Profit | -$26.23M | -$24.24M | -$94.49M | -$28.89M | -$20.86M |
| Net Non-Operating Interest Income (Expense) | $3.43M | $1.83M | $5.91M | $1.56M | $1.93M |
| Non-Operating Interest Income | $4.53M | $2.90M | $7.54M | $2.44M | $2.43M |
| Non-Operating Interest Expense | $1.10M | $1.07M | $1.64M | $876,000.00 | $495,000.00 |
| Other Income (Expense) | -$25,000.00 | -$152,000.00 | -$190,000.00 | -$27,000.00 | -$86,000.00 |
| Other Non-Operating Income (Expenses) | -$25,000.00 | -$152,000.00 | -$190,000.00 | -$27,000.00 | -$86,000.00 |
| Pretax Profit | -$22.83M | -$22.56M | -$88.77M | -$27.36M | -$19.01M |
| Tax | $0.00 | $0.00 | -$681,000.00 | $0.00 | $0.00 |
| Net Profit | -$22.83M | -$22.56M | -$88.09M | -$27.36M | -$19.01M |
| Profit from Continuing Operations | -$22.83M | -$22.56M | -$88.09M | -$27.36M | -$19.01M |
| Net Income to Parent Company | -$22.83M | -$22.56M | -$88.09M | -$27.36M | -$19.01M |
| Net Income to Common Stockholders | -$22.83M | -$22.56M | -$88.09M | -$27.36M | -$19.01M |
| Basic EPS | -$0.12 | -$0.18 | -$1.00 | -$0.27 | -$0.21 |
| Diluted EPS | -$0.12 | -$0.18 | -$1.00 | -$0.27 | -$0.21 |
Balance sheet
| Line item | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Total Assets | $527.21M | $335.63M | $279.93M | $279.93M | $218.45M |
| Total Current Assets | $334.82M | $334.68M | $278.19M | $278.19M | $216.62M |
| Cash and Cash Equivalents & Short-Term Investments | $326.28M | $331.54M | $273.46M | $273.46M | $210.78M |
| -Cash and Cash Equivalents | $63.01M | $97.60M | $43.76M | $43.76M | $61.24M |
| -Short Term Investments | $263.27M | $233.94M | $229.70M | $229.70M | $149.54M |
| Receivables | $3.34M | $1.67M | $1.74M | $1.74M | $1.39M |
| -Accounts Receivable | $3.34M | $1.67M | $1.22M | $1.22M | $845,000.00 |
| -Taxes Receivable | $0.00 | $0.00 | $518,000.00 | $518,000.00 | $547,000.00 |
| Restricted Cash | $42,000.00 | $42,000.00 | $42,000.00 | $42,000.00 | $42,000.00 |
| Other Current Assets | $5.15M | $1.43M | $2.96M | $2.96M | $4.41M |
| Total Non-Current Assets | $192.40M | $954,000.00 | $1.74M | $1.74M | $1.83M |
| Net PPE | $60,000.00 | $208,000.00 | $312,000.00 | $312,000.00 | $337,000.00 |
| -Gross PPE | $60,000.00 | $208,000.00 | $2.64M | $2.64M | $337,000.00 |
| Investments and Advances | $192.25M | – | – | – | – |
| Other Non-Current Assets | $90,000.00 | $746,000.00 | $1.43M | $1.43M | $1.50M |
| Total Liabilities | $53.00M | $51.64M | $55.04M | $55.04M | $32.85M |
| Total Current Liabilities | $12.50M | $11.32M | $15.00M | $15.00M | $12.61M |
| Payables | $1.27M | $1.53M | $2.72M | $2.72M | $4.80M |
| -Accounts Payable | $1.27M | $1.53M | $2.72M | $2.72M | $4.80M |
| Current Accrued Expenses | $10.96M | $9.53M | $12.02M | $12.02M | $7.56M |
| Short-Term Debt and Capital Lease Obligation | $274,000.00 | $265,000.00 | $256,000.00 | $256,000.00 | $247,000.00 |
| -Current Capital Lease Obligation | $274,000.00 | $265,000.00 | $256,000.00 | $256,000.00 | $247,000.00 |
| Total Non-Current Liabilities | $40.50M | $40.32M | $40.04M | $40.04M | $20.24M |
| Long Term Debt and Capital Lease Obligation | $35.75M | $35.58M | $35.43M | $35.43M | $15.66M |
| -Long Term Debt | $34.74M | $34.51M | $34.29M | $34.29M | $14.45M |
| -Long Term Capital Lease Obligation | $1.00M | $1.08M | $1.15M | $1.15M | $1.21M |
| Non-Current Deferred Liabilities | $147,000.00 | $147,000.00 | $160,000.00 | $160,000.00 | – |
| Other Non-Current Liabilities | $4.61M | $4.59M | $4.45M | $4.45M | $4.58M |
| Total Equity | $474.21M | $283.99M | $224.89M | $224.89M | $185.60M |
| Stockholders' Equity | $474.21M | $283.99M | $224.89M | $224.89M | $185.60M |
| Capital Stock | $19,000.00 | $13,000.00 | $11,000.00 | $11,000.00 | $10,000.00 |
| -Common Stock | $19,000.00 | $13,000.00 | $11,000.00 | $11,000.00 | $10,000.00 |
| Additional Paid-In Capital | $1.18B | $961.24M | $879.29M | $879.29M | $812.73M |
| Retained Earnings | -$694.87M | -$672.05M | -$649.48M | -$649.48M | -$622.13M |
| Gains/Losses Not Affecting Retained Earnings | -$6.04M | -$5.22M | -$4.93M | -$4.93M | -$5.02M |
| -Accumulated Depreciation | – | – | -$2.33M | -$2.33M | – |
Cash flow
| Line item | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$24.22M | -$20.94M | -$67.54M | -$19.45M | -$11.90M |
| Net cash flow from continuing operations | -$24.22M | -$20.94M | -$67.54M | -$19.45M | -$11.90M |
| Net Income from Continuing Operations | -$22.83M | -$22.56M | -$88.09M | -$27.36M | -$19.01M |
| Gain/Loss from Continuing Operations | $22,000.00 | $154,000.00 | $160,000.00 | $44,000.00 | $86,000.00 |
| Depreciation & Depletion & Amortization | $23,000.00 | $23,000.00 | $112,000.00 | $26,000.00 | $27,000.00 |
| Deferred Tax | $0.00 | $0.00 | -$681,000.00 | $0.00 | $0.00 |
| Other Non-Cash Items | $237,000.00 | $218,000.00 | $363,000.00 | $192,000.00 | $113,000.00 |
| Change in Working Capital | -$4.27M | -$1.99M | $6.75M | $3.62M | $3.53M |
| -Change in Receivables | -$1.68M | $72,000.00 | $2.06M | -$345,000.00 | -$514,000.00 |
| -Change in Prepaid Assets | -$3.72M | $1.62M | -$204,000.00 | $1.70M | -$8,000.00 |
| -Change in Payables and Accrued Expense | $1.13M | -$3.68M | $4.90M | $2.26M | $4.06M |
| Net cash flow from investing | -$221.44M | -$3.69M | -$132.47M | -$79.16M | -$149.32M |
| Net Cash Flow from Continuing Investing Activities | -$221.44M | -$3.69M | -$132.47M | -$79.16M | -$149.32M |
| Net PPE Purchase and Sale | -$32,000.00 | -$21,000.00 | -$11,000.00 | -$1,000.00 | $0.00 |
| Net Investment Purchase and Sale | -$221.41M | -$3.67M | -$132.46M | -$79.16M | -$149.32M |
| Financing Cash Flow | $211.07M | $78.47M | $206.84M | $81.13M | $39.35M |
| Net Cash Flow from Continuing Financing Activities | $211.07M | $78.47M | $206.84M | $81.13M | $39.35M |
| Net Common Stock Issuance | $210.80M | $79.26M | $173.73M | $61.35M | $40.11M |
| Net Other Financing Charges | $275,000.00 | -$784,000.00 | -$2.22M | -$515,000.00 | -$1.20M |
| Ending Cash Balance | $63.05M | $97.64M | $43.80M | $43.80M | $61.28M |
| Net Change in Cash | -$34.59M | $53.84M | $6.83M | -$17.48M | -$121.87M |
| Beginning Cash Balance | $97.64M | $43.80M | $36.97M | $61.28M | $183.15M |
| Free Cash Flow | -$24.25M | -$20.96M | -$67.55M | -$19.45M | -$11.90M |
| Proceeds from Stock Option Exercised | – | $0.00 | $332,000.00 | $291,000.00 | – |
| Net Issuance Payments Of Debt | – | – | $35.00M | $20.00M | $404,000.00 |
No comments yet — be the first to weigh in on ALT.
Sign in to join the discussion.